Literature DB >> 6199659

Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422.

M A Cascieri, H G Bull, R A Mumford, A A Patchett, N A Thornberry, T Liang.   

Abstract

The hydrolysis of substance P is catalyzed by purified rabbit lung angiotensin-converting enzyme (peptidyldipeptide hydrolase, EC 3.4.15.1). The kcat/Km for the reaction at 37 degrees is 3.3 +/- 0.3 X 10(3) M-1 sec-1, which is 60 times less than that which has been reported for the hydrolysis of angiotensin I. The initial site of hydrolysis is the antipenultimate peptide bond, which generates the tripeptide amide (Gly-Leu-Met-NH2). This hydrolysis is inhibited by the angiotensin-converting enzyme inhibitors captopril, MK-422, and EDTA, and is dependent on the concentration of chloride ion. Both captopril and MK-422 potentiate the substance P-induced stimulation of salivation in rats. Thus, angiotensin-converting enzyme may be one of the enzymes that degrade substance P in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199659

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

1.  The metabolism of neuropeptides. Endopeptidase-24.11 in human synaptic membrane preparations hydrolyses substance P.

Authors:  R Matsas; M Rattray; A J Kenny; A J Turner
Journal:  Biochem J       Date:  1985-06-01       Impact factor: 3.857

2.  Mnemogenic effects of injecting RA-octil, a CE-inhibitor derivate, systemically or into the basal forebrain.

Authors:  P Gerhardt; R U Hasenöhrl; F J Hock; J P Huston
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  Hydrolysis of substance P in the presence of the osteosarcoma cell line SaOS-2: release of free amino acids.

Authors:  Antonella Cavazza; Mario Marini; L Giorgio Roda; Umberto Tarantino; Angela Valenti
Journal:  Neurochem Res       Date:  2011-08-21       Impact factor: 3.996

4.  Angiotensin-converting enzyme inhibition, cough and the serum concentration of substance P.

Authors:  H Thysell; K E Andersson; S I Andersson; R Ekman
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin-induced contractions of guinea-pig isolated trachea.

Authors:  P Devillier; C Advenier; G Drapeau; J Marsac; D Regoli
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

6.  Peptidase modulation of the pulmonary effects of tachykinins in tracheal superfused guinea pig lungs.

Authors:  M A Martins; S A Shore; N P Gerard; C Gerard; J M Drazen
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Novel activity of human angiotensin I converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormone-releasing hormone.

Authors:  R A Skidgel; E G Erdös
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

8.  Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide.

Authors:  P Dubreuil; P Fulcrand; M Rodriguez; H Fulcrand; J Laur; J Martinez
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

9.  The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.

Authors:  Takashi Yamamoto; Padma Nair; Shou-wu Ma; Peg Davis; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2009-08-21       Impact factor: 3.641

10.  Lack of effect of enalaprilat on the action of vasoactive intestinal polypeptide in the human forearm.

Authors:  J R Cockcroft; P Chowienczyk; T G Elliott; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.